Kovačević, Ana

Link to this page

Authority KeyName Variants
8f385942-8dff-4f5e-98d6-391c7227bd9e
  • Kovačević, Ana (7)
Projects

Author's Bibliography

Supplementary information for the article: Mladenovic Stokanic, M.; Simovic, A.; Jovanovic, V.; Radomirovic, M.; Udovicki, B.; Krstic Ristivojevic, M.; Djukic, T.; Vasovic, T.; Acimovic, J.; Sabljic, L.; Lukic, I.; Kovacevic, A.; Cujic, D.; Gnjatovic, M.; Smiljanic, K.; Stojadinovic, M.; Radosavljevic, J.; Stanic-Vucinic, D.; Stojanovic, M.; Rajkovic, A.; Cirkovic Velickovic, T. Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species. International Journal of Molecular Sciences 2024, 25 (1), 333. https://doi.org/10.3390/ijms25010333.

Mladenović Stokanić, Maja; Simović, Ana; Jovanović, Vesna; Radomirović, Mirjana; Udovički, Božidar; Krstić Ristivojević, Maja; Djukić, Teodora; Vasović, Tamara; Aćimović, Jelena; Sabljić, Ljiljana; Lukić, Ivana; Kovačević, Ana; Cujic, Danica; Gnjatović, Marija; Smiljanić, Katarina; Stojadinović, Marija; Radosavljević, Jelena; Stanić-Vučinić, Dragana; Stojanović, Marijana; Rajković, Andreja; Ćirkovic Veličković, Tanja

(MDPI, 2024)

TY  - DATA
AU  - Mladenović Stokanić, Maja
AU  - Simović, Ana
AU  - Jovanović, Vesna
AU  - Radomirović, Mirjana
AU  - Udovički, Božidar
AU  - Krstić Ristivojević, Maja
AU  - Djukić, Teodora
AU  - Vasović, Tamara
AU  - Aćimović, Jelena
AU  - Sabljić, Ljiljana
AU  - Lukić, Ivana
AU  - Kovačević, Ana
AU  - Cujic, Danica
AU  - Gnjatović, Marija
AU  - Smiljanić, Katarina
AU  - Stojadinović, Marija
AU  - Radosavljević, Jelena
AU  - Stanić-Vučinić, Dragana
AU  - Stojanović, Marijana
AU  - Rajković, Andreja
AU  - Ćirkovic Veličković, Tanja
PY  - 2024
UR  - http://intor.torlakinstitut.com/handle/123456789/859
AB  - S1.1. Checking of N protein purity Recombinant N protein purity was checked after imidazole removal and buffer exchange by SDS PAGE (Figure 6.). For comparison, commercial high-purity HSA was also analyzed. S1.2. Identification of N protein Tandem mass spectrometry identification of proteins in an in-gel digested band of N protein (Figure S1, lane 3), confirmed the identity of N protein with high scores and peptide coverage (Fig. S2.). S2. Purification of polyclonal antibodies from mice and rabbit sera For the development of an ELISA test specific for the detection of SARS-CoV-2 N protein, recombinantly produced N protein was used for the immunization of mice and rabbits. Sera obtained from rabbits and mice were then tested for titer and specificity (Figure S3 and Figure 1). To determine the titer of polyclonal sera required to detect N protein in samples, we use wells coated with N protein and serial dilution of sera pools from different animals. After multiple washing steps, we detected the binding of rabbit and mice antibodies using secondary biotinylated antibodies and streptavidin-alkaline phosphatase chimaera or secondary antibodies with previously coupled alkaline phosphatase, where the amount of enzymes’ substrate converted to the product was measured as an increase in absorbance at 405 nm. As shown in Figure S3A, unpurified sera pools from both animals showed very high titers and expected logarithmic decrease of signal with dilution. Based on the obtained data titer for unpurified sera was determined to be X. The same trend was observed for pools purified using AS precipitation and rabbit sera purified using protein A affinity chromatography (Figure S3B and S3C). As shown in Figure S3D, clear bands from antibodies could be observed in both full and purified samples. Western blot analysis showed only one protein band on mass around 40 kDa, a Accession number / Protein Name Score Coverage (%) Unique peptides P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2, 46 kDa 504.9 74.22 183 mass of purified N protein suggesting that the obtained sera is highly specific for N protein (Figure 2). Section S3 Diagnostic validationS3.1. Stabilization of capture antibodies Pre-coated ELISA plates were prepared for usage in clinical practice. To ensure the preservation of the biofunctionality of the surface-bound capture antibodies, the commonly used stabilizing excipient, 3% sucrose with 10% glycerol in MilliQ water was used. The plates were incubated with 300 μL per well of a stabilizing agent for 1 hour at room temperature. After an hour of incubation, the solution was carefully aspirated from each well. The plate was then blotted against clear paper towels to remove any remaining liquid, and the plates were allowed to air dry for 3 hours at RT. Dried plates were wrapped in parafilm and stored at 4 °C for later use. To remove the stabilizing agent coating, wells were washed with slightly acidic distilled water (pH of 6) three times, leaving the plate prepared for subsequent assay steps. Section S4. Characterization of N protein by HRMS S4.1. SDS PAGE and in-gel digestion Characterization of the produced recombinant N protein was done by HRMS after its in-gel digestion. A total of 10 μg of purified protein(s) were loaded in a 0.5 cm wide well and after SDSPAGE gel was stained with Coomassie Brilliant Blue R-250 (CBB). Protein gel bands were washed, reduced with dithiothreitol, and alkylated with iodoacetamide, followed by in-gel trypsin digestion1 (Shevchenko et al. 2006) with some minor modifications. The amount of trypsin was leveled to a trypsin/sample ratio of 1:30 (w/w). The final concentration of MS-grade trypsin (diluted in 25 mM ammonium bicarbonate buffer) was 1 ng/μL. Sample clean-up was performed using zip tips HyperSep C18 (Thermo Fisher Scientific Inc., Bremen, Germany). S5.1 Immunization of rabbits and mice Mice immunization Swiss Webster mice (n=10) were immunized subcutaneously with N protein formulated with Complete Freund`s adjuvant (CFA; 1st dose, 100 μg N protein / dose) or Incomplete Freund`s adjuvant (IFA; 2nd and 3rd doses, 50 μg N protein / dose) in three-week intervals. Mice were housed in small groups of up to six animals and had access to commercial mice food and water ad libitum. N protein solution (500ug/ml in PBS) was sterilized by filtering through 0.22 um filters. Sterile N protein solution was mixed with CFA (Sigma, Cat. No. F5881) at ratio 1:1 (v/v) under aseptic conditions. In total 400 ul of N protein-CFA emulsion (N protein final concentration 250ug/ml) was applied per immunization per mouse. Initial immunization was done by injection of N protein in CFA given subcutaneously (SC) in four sites (thigh pocket, base of tail, and mediastinum) with a 100 ul using 23-25 gauge needle. In total 100 ug of N protein was applied per mouse (25 ug per site). Subsequent immunizations with booster doses were done in the same way, but using IFA (Sigma, Cat. No. F5506) instead of CFA and N protein final concentration was 125 ug/ml. . In total 50 ug of N protein was applied per mouse (12.5 ug per site). Immunizations were done every three weeks. Mice immunization scheme: 1. day 0 – N protein in PBS: CFA = 1:1 (v/v); N protein final concentration was 250 μg/mL; 400 μL per mice (4x100 μL), e.g. 100 μg per mice 2. day 21 - N protein in PBS: IFA = 1:1 (v/v); N protein final concentration was 125 μg/mL; 400 μL per mice (4x100 μL), e.g. 50 μg per mice 3. day 42 - N protein in PBS: IFA = 1:1 (v/v); N protein final concentration was 125 μg/mL; 400 μl per mice (4x100 μL), e.g. 50 μg per mice First bleeding was performed two weeks after the 3rd dose, and then in intervals not shorter than two weeks. The sera obtained after the first bleeding was tested for the production of specific anti-N protein antibodies.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Supplementary information for the article:       Mladenovic Stokanic, M.; Simovic, A.; Jovanovic, V.; Radomirovic, M.; Udovicki, B.; Krstic Ristivojevic, M.; Djukic, T.; Vasovic, T.; Acimovic, J.; Sabljic, L.; Lukic, I.; Kovacevic, A.; Cujic, D.; Gnjatovic, M.; Smiljanic, K.; Stojadinovic, M.; Radosavljevic, J.; Stanic-Vucinic, D.; Stojanovic, M.; Rajkovic, A.; Cirkovic Velickovic, T. Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species. International Journal of Molecular Sciences 2024, 25 (1), 333. https://doi.org/10.3390/ijms25010333.
IS  - 1
VL  - 25
UR  - https://hdl.handle.net/21.15107/rcub_intor_859
ER  - 
@misc{
author = "Mladenović Stokanić, Maja and Simović, Ana and Jovanović, Vesna and Radomirović, Mirjana and Udovički, Božidar and Krstić Ristivojević, Maja and Djukić, Teodora and Vasović, Tamara and Aćimović, Jelena and Sabljić, Ljiljana and Lukić, Ivana and Kovačević, Ana and Cujic, Danica and Gnjatović, Marija and Smiljanić, Katarina and Stojadinović, Marija and Radosavljević, Jelena and Stanić-Vučinić, Dragana and Stojanović, Marijana and Rajković, Andreja and Ćirkovic Veličković, Tanja",
year = "2024",
abstract = "S1.1. Checking of N protein purity Recombinant N protein purity was checked after imidazole removal and buffer exchange by SDS PAGE (Figure 6.). For comparison, commercial high-purity HSA was also analyzed. S1.2. Identification of N protein Tandem mass spectrometry identification of proteins in an in-gel digested band of N protein (Figure S1, lane 3), confirmed the identity of N protein with high scores and peptide coverage (Fig. S2.). S2. Purification of polyclonal antibodies from mice and rabbit sera For the development of an ELISA test specific for the detection of SARS-CoV-2 N protein, recombinantly produced N protein was used for the immunization of mice and rabbits. Sera obtained from rabbits and mice were then tested for titer and specificity (Figure S3 and Figure 1). To determine the titer of polyclonal sera required to detect N protein in samples, we use wells coated with N protein and serial dilution of sera pools from different animals. After multiple washing steps, we detected the binding of rabbit and mice antibodies using secondary biotinylated antibodies and streptavidin-alkaline phosphatase chimaera or secondary antibodies with previously coupled alkaline phosphatase, where the amount of enzymes’ substrate converted to the product was measured as an increase in absorbance at 405 nm. As shown in Figure S3A, unpurified sera pools from both animals showed very high titers and expected logarithmic decrease of signal with dilution. Based on the obtained data titer for unpurified sera was determined to be X. The same trend was observed for pools purified using AS precipitation and rabbit sera purified using protein A affinity chromatography (Figure S3B and S3C). As shown in Figure S3D, clear bands from antibodies could be observed in both full and purified samples. Western blot analysis showed only one protein band on mass around 40 kDa, a Accession number / Protein Name Score Coverage (%) Unique peptides P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2, 46 kDa 504.9 74.22 183 mass of purified N protein suggesting that the obtained sera is highly specific for N protein (Figure 2). Section S3 Diagnostic validationS3.1. Stabilization of capture antibodies Pre-coated ELISA plates were prepared for usage in clinical practice. To ensure the preservation of the biofunctionality of the surface-bound capture antibodies, the commonly used stabilizing excipient, 3% sucrose with 10% glycerol in MilliQ water was used. The plates were incubated with 300 μL per well of a stabilizing agent for 1 hour at room temperature. After an hour of incubation, the solution was carefully aspirated from each well. The plate was then blotted against clear paper towels to remove any remaining liquid, and the plates were allowed to air dry for 3 hours at RT. Dried plates were wrapped in parafilm and stored at 4 °C for later use. To remove the stabilizing agent coating, wells were washed with slightly acidic distilled water (pH of 6) three times, leaving the plate prepared for subsequent assay steps. Section S4. Characterization of N protein by HRMS S4.1. SDS PAGE and in-gel digestion Characterization of the produced recombinant N protein was done by HRMS after its in-gel digestion. A total of 10 μg of purified protein(s) were loaded in a 0.5 cm wide well and after SDSPAGE gel was stained with Coomassie Brilliant Blue R-250 (CBB). Protein gel bands were washed, reduced with dithiothreitol, and alkylated with iodoacetamide, followed by in-gel trypsin digestion1 (Shevchenko et al. 2006) with some minor modifications. The amount of trypsin was leveled to a trypsin/sample ratio of 1:30 (w/w). The final concentration of MS-grade trypsin (diluted in 25 mM ammonium bicarbonate buffer) was 1 ng/μL. Sample clean-up was performed using zip tips HyperSep C18 (Thermo Fisher Scientific Inc., Bremen, Germany). S5.1 Immunization of rabbits and mice Mice immunization Swiss Webster mice (n=10) were immunized subcutaneously with N protein formulated with Complete Freund`s adjuvant (CFA; 1st dose, 100 μg N protein / dose) or Incomplete Freund`s adjuvant (IFA; 2nd and 3rd doses, 50 μg N protein / dose) in three-week intervals. Mice were housed in small groups of up to six animals and had access to commercial mice food and water ad libitum. N protein solution (500ug/ml in PBS) was sterilized by filtering through 0.22 um filters. Sterile N protein solution was mixed with CFA (Sigma, Cat. No. F5881) at ratio 1:1 (v/v) under aseptic conditions. In total 400 ul of N protein-CFA emulsion (N protein final concentration 250ug/ml) was applied per immunization per mouse. Initial immunization was done by injection of N protein in CFA given subcutaneously (SC) in four sites (thigh pocket, base of tail, and mediastinum) with a 100 ul using 23-25 gauge needle. In total 100 ug of N protein was applied per mouse (25 ug per site). Subsequent immunizations with booster doses were done in the same way, but using IFA (Sigma, Cat. No. F5506) instead of CFA and N protein final concentration was 125 ug/ml. . In total 50 ug of N protein was applied per mouse (12.5 ug per site). Immunizations were done every three weeks. Mice immunization scheme: 1. day 0 – N protein in PBS: CFA = 1:1 (v/v); N protein final concentration was 250 μg/mL; 400 μL per mice (4x100 μL), e.g. 100 μg per mice 2. day 21 - N protein in PBS: IFA = 1:1 (v/v); N protein final concentration was 125 μg/mL; 400 μL per mice (4x100 μL), e.g. 50 μg per mice 3. day 42 - N protein in PBS: IFA = 1:1 (v/v); N protein final concentration was 125 μg/mL; 400 μl per mice (4x100 μL), e.g. 50 μg per mice First bleeding was performed two weeks after the 3rd dose, and then in intervals not shorter than two weeks. The sera obtained after the first bleeding was tested for the production of specific anti-N protein antibodies.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Supplementary information for the article:       Mladenovic Stokanic, M.; Simovic, A.; Jovanovic, V.; Radomirovic, M.; Udovicki, B.; Krstic Ristivojevic, M.; Djukic, T.; Vasovic, T.; Acimovic, J.; Sabljic, L.; Lukic, I.; Kovacevic, A.; Cujic, D.; Gnjatovic, M.; Smiljanic, K.; Stojadinovic, M.; Radosavljevic, J.; Stanic-Vucinic, D.; Stojanovic, M.; Rajkovic, A.; Cirkovic Velickovic, T. Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species. International Journal of Molecular Sciences 2024, 25 (1), 333. https://doi.org/10.3390/ijms25010333.",
number = "1",
volume = "25",
url = "https://hdl.handle.net/21.15107/rcub_intor_859"
}
Mladenović Stokanić, M., Simović, A., Jovanović, V., Radomirović, M., Udovički, B., Krstić Ristivojević, M., Djukić, T., Vasović, T., Aćimović, J., Sabljić, L., Lukić, I., Kovačević, A., Cujic, D., Gnjatović, M., Smiljanić, K., Stojadinović, M., Radosavljević, J., Stanić-Vučinić, D., Stojanović, M., Rajković, A.,& Ćirkovic Veličković, T.. (2024). Supplementary information for the article:       Mladenovic Stokanic, M.; Simovic, A.; Jovanovic, V.; Radomirovic, M.; Udovicki, B.; Krstic Ristivojevic, M.; Djukic, T.; Vasovic, T.; Acimovic, J.; Sabljic, L.; Lukic, I.; Kovacevic, A.; Cujic, D.; Gnjatovic, M.; Smiljanic, K.; Stojadinovic, M.; Radosavljevic, J.; Stanic-Vucinic, D.; Stojanovic, M.; Rajkovic, A.; Cirkovic Velickovic, T. Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species. International Journal of Molecular Sciences 2024, 25 (1), 333. https://doi.org/10.3390/ijms25010333.. in International Journal of Molecular Sciences
MDPI., 25(1).
https://hdl.handle.net/21.15107/rcub_intor_859
Mladenović Stokanić M, Simović A, Jovanović V, Radomirović M, Udovički B, Krstić Ristivojević M, Djukić T, Vasović T, Aćimović J, Sabljić L, Lukić I, Kovačević A, Cujic D, Gnjatović M, Smiljanić K, Stojadinović M, Radosavljević J, Stanić-Vučinić D, Stojanović M, Rajković A, Ćirkovic Veličković T. Supplementary information for the article:       Mladenovic Stokanic, M.; Simovic, A.; Jovanovic, V.; Radomirovic, M.; Udovicki, B.; Krstic Ristivojevic, M.; Djukic, T.; Vasovic, T.; Acimovic, J.; Sabljic, L.; Lukic, I.; Kovacevic, A.; Cujic, D.; Gnjatovic, M.; Smiljanic, K.; Stojadinovic, M.; Radosavljevic, J.; Stanic-Vucinic, D.; Stojanovic, M.; Rajkovic, A.; Cirkovic Velickovic, T. Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species. International Journal of Molecular Sciences 2024, 25 (1), 333. https://doi.org/10.3390/ijms25010333.. in International Journal of Molecular Sciences. 2024;25(1).
https://hdl.handle.net/21.15107/rcub_intor_859 .
Mladenović Stokanić, Maja, Simović, Ana, Jovanović, Vesna, Radomirović, Mirjana, Udovički, Božidar, Krstić Ristivojević, Maja, Djukić, Teodora, Vasović, Tamara, Aćimović, Jelena, Sabljić, Ljiljana, Lukić, Ivana, Kovačević, Ana, Cujic, Danica, Gnjatović, Marija, Smiljanić, Katarina, Stojadinović, Marija, Radosavljević, Jelena, Stanić-Vučinić, Dragana, Stojanović, Marijana, Rajković, Andreja, Ćirkovic Veličković, Tanja, "Supplementary information for the article:       Mladenovic Stokanic, M.; Simovic, A.; Jovanovic, V.; Radomirovic, M.; Udovicki, B.; Krstic Ristivojevic, M.; Djukic, T.; Vasovic, T.; Acimovic, J.; Sabljic, L.; Lukic, I.; Kovacevic, A.; Cujic, D.; Gnjatovic, M.; Smiljanic, K.; Stojadinovic, M.; Radosavljevic, J.; Stanic-Vucinic, D.; Stojanovic, M.; Rajkovic, A.; Cirkovic Velickovic, T. Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species. International Journal of Molecular Sciences 2024, 25 (1), 333. https://doi.org/10.3390/ijms25010333." in International Journal of Molecular Sciences, 25, no. 1 (2024),
https://hdl.handle.net/21.15107/rcub_intor_859 .

Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species

Mladenović Stokanić, Maja; Simović, Ana; Jovanović, Vesna; Radomirović, Mirjana; Udovički, Božidar; Krstić Ristivojević, Maja; Djukić, Teodora; Vasović, Tamara; Aćimović, Jelena; Sabljić, Ljiljana; Lukić, Ivana; Kovačević, Ana; Cujic, Danica; Gnjatović, Marija; Smiljanić, Katarina; Stojadinović, Marija; Radosavljević, Jelena; Stanić-Vučinić, Dragana; Stojanović, Marijana; Rajković, Andreja; Ćirkovic Veličković, Tanja

(MDPI, 2024)

TY  - JOUR
AU  - Mladenović Stokanić, Maja
AU  - Simović, Ana
AU  - Jovanović, Vesna
AU  - Radomirović, Mirjana
AU  - Udovički, Božidar
AU  - Krstić Ristivojević, Maja
AU  - Djukić, Teodora
AU  - Vasović, Tamara
AU  - Aćimović, Jelena
AU  - Sabljić, Ljiljana
AU  - Lukić, Ivana
AU  - Kovačević, Ana
AU  - Cujic, Danica
AU  - Gnjatović, Marija
AU  - Smiljanić, Katarina
AU  - Stojadinović, Marija
AU  - Radosavljević, Jelena
AU  - Stanić-Vučinić, Dragana
AU  - Stojanović, Marijana
AU  - Rajković, Andreja
AU  - Ćirkovic Veličković, Tanja
PY  - 2024
UR  - http://intor.torlakinstitut.com/handle/123456789/858
AB  - In this study, a cost-effective sandwich ELISA test, based on polyclonal antibodies, for routine quantification SARS-CoV-2 nucleocapsid (N) protein was developed. The recombinant N protein was produced and used for the production of mice and rabbit antisera. Polyclonal N protein-specific antibodies served as capture and detection antibodies. The prototype ELISA has LOD 0.93 ng/mL and LOQ 5.3 ng/mL, with a linear range of 1.52–48.83 ng/mL. N protein heat pretreatment (56 °C, 1 h) decreased, while pretreatment with 1% Triton X-100 increased analytical ELISA sensitivity. The diagnostic specificity of ELISA was 100% (95% CI, 91.19–100.00%) and sensitivity was 52.94% (95% CI, 35.13–70.22%) compared to rtRT-PCR (Ct < 40). Profoundly higher sensitivity was obtained using patient samples mostly containing Wuhan-similar variants (Wuhan, alpha, and delta), 62.50% (95% CI, 40.59 to 81.20%), in comparison to samples mostly containing Wuhan-distant variants (Omicron) 30.00% (6.67–65.25%). The developed product has relatively high diagnostic sensitivity in relation to its analytical sensitivity due to the usage of polyclonal antibodies from two species, providing a wide repertoire of antibodies against multiple N protein epitopes. Moreover, the fast, simple, and inexpensive production of polyclonal antibodies, as the most expensive assay components, would result in affordable antigen tests.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species
IS  - 1
SP  - 333
VL  - 25
DO  - 10.3390/ijms25010333
ER  - 
@article{
author = "Mladenović Stokanić, Maja and Simović, Ana and Jovanović, Vesna and Radomirović, Mirjana and Udovički, Božidar and Krstić Ristivojević, Maja and Djukić, Teodora and Vasović, Tamara and Aćimović, Jelena and Sabljić, Ljiljana and Lukić, Ivana and Kovačević, Ana and Cujic, Danica and Gnjatović, Marija and Smiljanić, Katarina and Stojadinović, Marija and Radosavljević, Jelena and Stanić-Vučinić, Dragana and Stojanović, Marijana and Rajković, Andreja and Ćirkovic Veličković, Tanja",
year = "2024",
abstract = "In this study, a cost-effective sandwich ELISA test, based on polyclonal antibodies, for routine quantification SARS-CoV-2 nucleocapsid (N) protein was developed. The recombinant N protein was produced and used for the production of mice and rabbit antisera. Polyclonal N protein-specific antibodies served as capture and detection antibodies. The prototype ELISA has LOD 0.93 ng/mL and LOQ 5.3 ng/mL, with a linear range of 1.52–48.83 ng/mL. N protein heat pretreatment (56 °C, 1 h) decreased, while pretreatment with 1% Triton X-100 increased analytical ELISA sensitivity. The diagnostic specificity of ELISA was 100% (95% CI, 91.19–100.00%) and sensitivity was 52.94% (95% CI, 35.13–70.22%) compared to rtRT-PCR (Ct < 40). Profoundly higher sensitivity was obtained using patient samples mostly containing Wuhan-similar variants (Wuhan, alpha, and delta), 62.50% (95% CI, 40.59 to 81.20%), in comparison to samples mostly containing Wuhan-distant variants (Omicron) 30.00% (6.67–65.25%). The developed product has relatively high diagnostic sensitivity in relation to its analytical sensitivity due to the usage of polyclonal antibodies from two species, providing a wide repertoire of antibodies against multiple N protein epitopes. Moreover, the fast, simple, and inexpensive production of polyclonal antibodies, as the most expensive assay components, would result in affordable antigen tests.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species",
number = "1",
pages = "333",
volume = "25",
doi = "10.3390/ijms25010333"
}
Mladenović Stokanić, M., Simović, A., Jovanović, V., Radomirović, M., Udovički, B., Krstić Ristivojević, M., Djukić, T., Vasović, T., Aćimović, J., Sabljić, L., Lukić, I., Kovačević, A., Cujic, D., Gnjatović, M., Smiljanić, K., Stojadinović, M., Radosavljević, J., Stanić-Vučinić, D., Stojanović, M., Rajković, A.,& Ćirkovic Veličković, T.. (2024). Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species. in International Journal of Molecular Sciences
MDPI., 25(1), 333.
https://doi.org/10.3390/ijms25010333
Mladenović Stokanić M, Simović A, Jovanović V, Radomirović M, Udovički B, Krstić Ristivojević M, Djukić T, Vasović T, Aćimović J, Sabljić L, Lukić I, Kovačević A, Cujic D, Gnjatović M, Smiljanić K, Stojadinović M, Radosavljević J, Stanić-Vučinić D, Stojanović M, Rajković A, Ćirkovic Veličković T. Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species. in International Journal of Molecular Sciences. 2024;25(1):333.
doi:10.3390/ijms25010333 .
Mladenović Stokanić, Maja, Simović, Ana, Jovanović, Vesna, Radomirović, Mirjana, Udovički, Božidar, Krstić Ristivojević, Maja, Djukić, Teodora, Vasović, Tamara, Aćimović, Jelena, Sabljić, Ljiljana, Lukić, Ivana, Kovačević, Ana, Cujic, Danica, Gnjatović, Marija, Smiljanić, Katarina, Stojadinović, Marija, Radosavljević, Jelena, Stanić-Vučinić, Dragana, Stojanović, Marijana, Rajković, Andreja, Ćirkovic Veličković, Tanja, "Sandwich ELISA for the Quantification of Nucleocapsid Protein of SARS-CoV-2 Based on Polyclonal Antibodies from Two Different Species" in International Journal of Molecular Sciences, 25, no. 1 (2024):333,
https://doi.org/10.3390/ijms25010333 . .

Supplementary material for: Popović, M.; Stojanović, M.; Veličković, Z.; Kovačević, A.; Miljković, R.; Mirković, N.; Marinković, A. D. Characterization of Potential Probiotic Strain, L. Reuteri B2, and Its Microencapsulation Using Alginate-Based Biopolymers. International Journal of Biological Macromolecules 2021, 183, 423–434. https://doi.org/10.1016/j.ijbiomac.2021.04.177.

Popović, Mina; Stojanović, Marijana; Veličković, Zlate; Kovačević, Ana; Miljković, Radmila; Mirković, Nemanja; Marinković, Aleksandar D.

(Elsevier, 2021)

TY  - DATA
AU  - Popović, Mina
AU  - Stojanović, Marijana
AU  - Veličković, Zlate
AU  - Kovačević, Ana
AU  - Miljković, Radmila
AU  - Mirković, Nemanja
AU  - Marinković, Aleksandar D.
PY  - 2021
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/4596
UR  - http://intor.torlakinstitut.com/handle/123456789/627
AB  - Preparation of materials for encapsulation (Materials, Laboratory isolation of ricinoleic acid, Laboratory preparation of starch maleate monoester, Characterization, Statistical analysis). Additional results (Antimicrobial activity, Optimization of encapsulation yield, Size distribution of alginate beads in acidic conditions). additional references
PB  - Elsevier
T2  - International Journal of Biological Macromolecules
T1  - Supplementary material for: Popović, M.; Stojanović, M.; Veličković, Z.; Kovačević, A.; Miljković, R.; Mirković, N.; Marinković, A. D. Characterization of Potential Probiotic Strain, L. Reuteri B2, and Its Microencapsulation Using Alginate-Based Biopolymers. International Journal of Biological Macromolecules 2021, 183, 423–434. https://doi.org/10.1016/j.ijbiomac.2021.04.177.
UR  - https://hdl.handle.net/21.15107/rcub_intor_627
ER  - 
@misc{
author = "Popović, Mina and Stojanović, Marijana and Veličković, Zlate and Kovačević, Ana and Miljković, Radmila and Mirković, Nemanja and Marinković, Aleksandar D.",
year = "2021",
abstract = "Preparation of materials for encapsulation (Materials, Laboratory isolation of ricinoleic acid, Laboratory preparation of starch maleate monoester, Characterization, Statistical analysis). Additional results (Antimicrobial activity, Optimization of encapsulation yield, Size distribution of alginate beads in acidic conditions). additional references",
publisher = "Elsevier",
journal = "International Journal of Biological Macromolecules",
title = "Supplementary material for: Popović, M.; Stojanović, M.; Veličković, Z.; Kovačević, A.; Miljković, R.; Mirković, N.; Marinković, A. D. Characterization of Potential Probiotic Strain, L. Reuteri B2, and Its Microencapsulation Using Alginate-Based Biopolymers. International Journal of Biological Macromolecules 2021, 183, 423–434. https://doi.org/10.1016/j.ijbiomac.2021.04.177.",
url = "https://hdl.handle.net/21.15107/rcub_intor_627"
}
Popović, M., Stojanović, M., Veličković, Z., Kovačević, A., Miljković, R., Mirković, N.,& Marinković, A. D.. (2021). Supplementary material for: Popović, M.; Stojanović, M.; Veličković, Z.; Kovačević, A.; Miljković, R.; Mirković, N.; Marinković, A. D. Characterization of Potential Probiotic Strain, L. Reuteri B2, and Its Microencapsulation Using Alginate-Based Biopolymers. International Journal of Biological Macromolecules 2021, 183, 423–434. https://doi.org/10.1016/j.ijbiomac.2021.04.177.. in International Journal of Biological Macromolecules
Elsevier..
https://hdl.handle.net/21.15107/rcub_intor_627
Popović M, Stojanović M, Veličković Z, Kovačević A, Miljković R, Mirković N, Marinković AD. Supplementary material for: Popović, M.; Stojanović, M.; Veličković, Z.; Kovačević, A.; Miljković, R.; Mirković, N.; Marinković, A. D. Characterization of Potential Probiotic Strain, L. Reuteri B2, and Its Microencapsulation Using Alginate-Based Biopolymers. International Journal of Biological Macromolecules 2021, 183, 423–434. https://doi.org/10.1016/j.ijbiomac.2021.04.177.. in International Journal of Biological Macromolecules. 2021;.
https://hdl.handle.net/21.15107/rcub_intor_627 .
Popović, Mina, Stojanović, Marijana, Veličković, Zlate, Kovačević, Ana, Miljković, Radmila, Mirković, Nemanja, Marinković, Aleksandar D., "Supplementary material for: Popović, M.; Stojanović, M.; Veličković, Z.; Kovačević, A.; Miljković, R.; Mirković, N.; Marinković, A. D. Characterization of Potential Probiotic Strain, L. Reuteri B2, and Its Microencapsulation Using Alginate-Based Biopolymers. International Journal of Biological Macromolecules 2021, 183, 423–434. https://doi.org/10.1016/j.ijbiomac.2021.04.177." in International Journal of Biological Macromolecules (2021),
https://hdl.handle.net/21.15107/rcub_intor_627 .
2
11

Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers

Popović, Mina; Stojanović, Marijana; Veličković, Zlate; Kovačević, Ana; Miljković, Radmila; Mirković, Nemanja; Marinković, Aleksandar D.

(Elsevier, 2021)

TY  - JOUR
AU  - Popović, Mina
AU  - Stojanović, Marijana
AU  - Veličković, Zlate
AU  - Kovačević, Ana
AU  - Miljković, Radmila
AU  - Mirković, Nemanja
AU  - Marinković, Aleksandar D.
PY  - 2021
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/4595
UR  - http://intor.torlakinstitut.com/handle/123456789/628
AB  - In this study, Lactobacillus reuteri B2was isolated fromthe feces of C57BL/6 mice and assessed on probiotic activity.L. reuteri B2was identified by 16S rDNA sequencing, which the cell viability in acidic conditions at pH 2.0was64% after 2 h, and in the presents of 0.30% of the bile salts, after 6 h, was 37%. Antimicrobial assay with L. reuteri B2showed maximumdiameters against Klebsiela oxytoca J7 (12.5±0.71mm).Wefurther hypothesized if L. reuteriB2 strain in the free form can survive all conditions in the gastrointestinal tract (GIT) then the utilization of theappropriate biomaterials would ameliorate its stability and viability in GIT. L. reuteri B2 was microencapsulatedinto sodium alginate-(Na-alg) and different content of Na-alg and sodium maleate (SM) beads. Characterizationmaterials enveloped their thermal characteristics (TGA/DTA analysis) and structure using: scanning electron microscopy(SEM), FTIR, and particle size distribution. The high survival rate of L. reuteri B2 at lowpH from2.0 to 4.0and in the presence of the bile salts, at concentrations up to 0.30%, was obtained. L. reuteri B2 showed strong antimicrobialactivity and the best protection microencapsulated with Na-alg + SM in simulated gastric juices(SGJ).
PB  - Elsevier
T2  - International Journal of Biological Macromolecules
T1  - Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers
EP  - 434
SP  - 423
VL  - 183
DO  - 10.1016/j.ijbiomac.2021.04.177
ER  - 
@article{
author = "Popović, Mina and Stojanović, Marijana and Veličković, Zlate and Kovačević, Ana and Miljković, Radmila and Mirković, Nemanja and Marinković, Aleksandar D.",
year = "2021",
abstract = "In this study, Lactobacillus reuteri B2was isolated fromthe feces of C57BL/6 mice and assessed on probiotic activity.L. reuteri B2was identified by 16S rDNA sequencing, which the cell viability in acidic conditions at pH 2.0was64% after 2 h, and in the presents of 0.30% of the bile salts, after 6 h, was 37%. Antimicrobial assay with L. reuteri B2showed maximumdiameters against Klebsiela oxytoca J7 (12.5±0.71mm).Wefurther hypothesized if L. reuteriB2 strain in the free form can survive all conditions in the gastrointestinal tract (GIT) then the utilization of theappropriate biomaterials would ameliorate its stability and viability in GIT. L. reuteri B2 was microencapsulatedinto sodium alginate-(Na-alg) and different content of Na-alg and sodium maleate (SM) beads. Characterizationmaterials enveloped their thermal characteristics (TGA/DTA analysis) and structure using: scanning electron microscopy(SEM), FTIR, and particle size distribution. The high survival rate of L. reuteri B2 at lowpH from2.0 to 4.0and in the presence of the bile salts, at concentrations up to 0.30%, was obtained. L. reuteri B2 showed strong antimicrobialactivity and the best protection microencapsulated with Na-alg + SM in simulated gastric juices(SGJ).",
publisher = "Elsevier",
journal = "International Journal of Biological Macromolecules",
title = "Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers",
pages = "434-423",
volume = "183",
doi = "10.1016/j.ijbiomac.2021.04.177"
}
Popović, M., Stojanović, M., Veličković, Z., Kovačević, A., Miljković, R., Mirković, N.,& Marinković, A. D.. (2021). Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers. in International Journal of Biological Macromolecules
Elsevier., 183, 423-434.
https://doi.org/10.1016/j.ijbiomac.2021.04.177
Popović M, Stojanović M, Veličković Z, Kovačević A, Miljković R, Mirković N, Marinković AD. Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers. in International Journal of Biological Macromolecules. 2021;183:423-434.
doi:10.1016/j.ijbiomac.2021.04.177 .
Popović, Mina, Stojanović, Marijana, Veličković, Zlate, Kovačević, Ana, Miljković, Radmila, Mirković, Nemanja, Marinković, Aleksandar D., "Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers" in International Journal of Biological Macromolecules, 183 (2021):423-434,
https://doi.org/10.1016/j.ijbiomac.2021.04.177 . .
15
2
11

Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers

Popović, Mina; Stojanović, Marijana; Veličković, Zlate; Kovačević, Ana; Miljković, Radmila; Mirković, Nemanja; Marinković, Aleksandar D.

(Elsevier, 2021)

TY  - JOUR
AU  - Popović, Mina
AU  - Stojanović, Marijana
AU  - Veličković, Zlate
AU  - Kovačević, Ana
AU  - Miljković, Radmila
AU  - Mirković, Nemanja
AU  - Marinković, Aleksandar D.
PY  - 2021
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/4594
UR  - http://intor.torlakinstitut.com/handle/123456789/626
AB  - In this study, Lactobacillus reuteri B2was isolated fromthe feces of C57BL/6 mice and assessed on probiotic activity.L. reuteri B2was identified by 16S rDNA sequencing, which the cell viability in acidic conditions at pH 2.0was64% after 2 h, and in the presents of 0.30% of the bile salts, after 6 h, was 37%. Antimicrobial assay with L. reuteri B2showed maximumdiameters against Klebsiela oxytoca J7 (12.5±0.71mm).Wefurther hypothesized if L. reuteriB2 strain in the free form can survive all conditions in the gastrointestinal tract (GIT) then the utilization of theappropriate biomaterials would ameliorate its stability and viability in GIT. L. reuteri B2 was microencapsulatedinto sodium alginate-(Na-alg) and different content of Na-alg and sodium maleate (SM) beads. Characterizationmaterials enveloped their thermal characteristics (TGA/DTA analysis) and structure using: scanning electron microscopy(SEM), FTIR, and particle size distribution. The high survival rate of L. reuteri B2 at lowpH from2.0 to 4.0and in the presence of the bile salts, at concentrations up to 0.30%, was obtained. L. reuteri B2 showed strong antimicrobialactivity and the best protection microencapsulated with Na-alg + SM in simulated gastric juices(SGJ).
PB  - Elsevier
T2  - International Journal of Biological Macromolecules
T1  - Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers
EP  - 434
SP  - 423
VL  - 183
DO  - 10.1016/j.ijbiomac.2021.04.177
ER  - 
@article{
author = "Popović, Mina and Stojanović, Marijana and Veličković, Zlate and Kovačević, Ana and Miljković, Radmila and Mirković, Nemanja and Marinković, Aleksandar D.",
year = "2021",
abstract = "In this study, Lactobacillus reuteri B2was isolated fromthe feces of C57BL/6 mice and assessed on probiotic activity.L. reuteri B2was identified by 16S rDNA sequencing, which the cell viability in acidic conditions at pH 2.0was64% after 2 h, and in the presents of 0.30% of the bile salts, after 6 h, was 37%. Antimicrobial assay with L. reuteri B2showed maximumdiameters against Klebsiela oxytoca J7 (12.5±0.71mm).Wefurther hypothesized if L. reuteriB2 strain in the free form can survive all conditions in the gastrointestinal tract (GIT) then the utilization of theappropriate biomaterials would ameliorate its stability and viability in GIT. L. reuteri B2 was microencapsulatedinto sodium alginate-(Na-alg) and different content of Na-alg and sodium maleate (SM) beads. Characterizationmaterials enveloped their thermal characteristics (TGA/DTA analysis) and structure using: scanning electron microscopy(SEM), FTIR, and particle size distribution. The high survival rate of L. reuteri B2 at lowpH from2.0 to 4.0and in the presence of the bile salts, at concentrations up to 0.30%, was obtained. L. reuteri B2 showed strong antimicrobialactivity and the best protection microencapsulated with Na-alg + SM in simulated gastric juices(SGJ).",
publisher = "Elsevier",
journal = "International Journal of Biological Macromolecules",
title = "Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers",
pages = "434-423",
volume = "183",
doi = "10.1016/j.ijbiomac.2021.04.177"
}
Popović, M., Stojanović, M., Veličković, Z., Kovačević, A., Miljković, R., Mirković, N.,& Marinković, A. D.. (2021). Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers. in International Journal of Biological Macromolecules
Elsevier., 183, 423-434.
https://doi.org/10.1016/j.ijbiomac.2021.04.177
Popović M, Stojanović M, Veličković Z, Kovačević A, Miljković R, Mirković N, Marinković AD. Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers. in International Journal of Biological Macromolecules. 2021;183:423-434.
doi:10.1016/j.ijbiomac.2021.04.177 .
Popović, Mina, Stojanović, Marijana, Veličković, Zlate, Kovačević, Ana, Miljković, Radmila, Mirković, Nemanja, Marinković, Aleksandar D., "Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers" in International Journal of Biological Macromolecules, 183 (2021):423-434,
https://doi.org/10.1016/j.ijbiomac.2021.04.177 . .
15
2
11

Supplementary information for the article: Stojanović, M.; Lukić, I.; Marinković, E.; Kovačević, A.; Miljković, R.; Tobias, J.; Schabussova, I.; Zlatović, M.; Barisani-Asenbauer, T.; Wiedermann, U.; Inić-Kanada, A. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. Vaccines 2020, 8 (4), 719. https://doi.org/10.3390/vaccines8040719.

Stojanović, Marijana; Lukić, Ivana; Marinković, Emilija; Kovačević, Ana; Miljković, Radmila; Tobias, Joshua; Schabussova, Irma; Zlatović, Mario; Barisani-Asenbauer, Talin; Wiedermann, Ursula; Inić-Kanada, Aleksandra

(MDPI, 2020)

TY  - DATA
AU  - Stojanović, Marijana
AU  - Lukić, Ivana
AU  - Marinković, Emilija
AU  - Kovačević, Ana
AU  - Miljković, Radmila
AU  - Tobias, Joshua
AU  - Schabussova, Irma
AU  - Zlatović, Mario
AU  - Barisani-Asenbauer, Talin
AU  - Wiedermann, Ursula
AU  - Inić-Kanada, Aleksandra
PY  - 2020
UR  - http://intor.torlakinstitut.com/handle/123456789/643
AB  - Table S1: Characteristics of selected anti-tetanus mAbs [35,36].
PB  - MDPI
T2  - Vaccines
T1  - Supplementary information for the article: Stojanović, M.; Lukić, I.; Marinković, E.; Kovačević, A.; Miljković, R.; Tobias, J.; Schabussova, I.; Zlatović, M.; Barisani-Asenbauer, T.; Wiedermann, U.; Inić-Kanada, A. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. Vaccines 2020, 8 (4), 719. https://doi.org/10.3390/vaccines8040719.
IS  - 4
SP  - 719
VL  - 8
UR  - https://hdl.handle.net/21.15107/rcub_intor_643
ER  - 
@misc{
author = "Stojanović, Marijana and Lukić, Ivana and Marinković, Emilija and Kovačević, Ana and Miljković, Radmila and Tobias, Joshua and Schabussova, Irma and Zlatović, Mario and Barisani-Asenbauer, Talin and Wiedermann, Ursula and Inić-Kanada, Aleksandra",
year = "2020",
abstract = "Table S1: Characteristics of selected anti-tetanus mAbs [35,36].",
publisher = "MDPI",
journal = "Vaccines",
title = "Supplementary information for the article: Stojanović, M.; Lukić, I.; Marinković, E.; Kovačević, A.; Miljković, R.; Tobias, J.; Schabussova, I.; Zlatović, M.; Barisani-Asenbauer, T.; Wiedermann, U.; Inić-Kanada, A. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. Vaccines 2020, 8 (4), 719. https://doi.org/10.3390/vaccines8040719.",
number = "4",
pages = "719",
volume = "8",
url = "https://hdl.handle.net/21.15107/rcub_intor_643"
}
Stojanović, M., Lukić, I., Marinković, E., Kovačević, A., Miljković, R., Tobias, J., Schabussova, I., Zlatović, M., Barisani-Asenbauer, T., Wiedermann, U.,& Inić-Kanada, A.. (2020). Supplementary information for the article: Stojanović, M.; Lukić, I.; Marinković, E.; Kovačević, A.; Miljković, R.; Tobias, J.; Schabussova, I.; Zlatović, M.; Barisani-Asenbauer, T.; Wiedermann, U.; Inić-Kanada, A. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. Vaccines 2020, 8 (4), 719. https://doi.org/10.3390/vaccines8040719.. in Vaccines
MDPI., 8(4), 719.
https://hdl.handle.net/21.15107/rcub_intor_643
Stojanović M, Lukić I, Marinković E, Kovačević A, Miljković R, Tobias J, Schabussova I, Zlatović M, Barisani-Asenbauer T, Wiedermann U, Inić-Kanada A. Supplementary information for the article: Stojanović, M.; Lukić, I.; Marinković, E.; Kovačević, A.; Miljković, R.; Tobias, J.; Schabussova, I.; Zlatović, M.; Barisani-Asenbauer, T.; Wiedermann, U.; Inić-Kanada, A. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. Vaccines 2020, 8 (4), 719. https://doi.org/10.3390/vaccines8040719.. in Vaccines. 2020;8(4):719.
https://hdl.handle.net/21.15107/rcub_intor_643 .
Stojanović, Marijana, Lukić, Ivana, Marinković, Emilija, Kovačević, Ana, Miljković, Radmila, Tobias, Joshua, Schabussova, Irma, Zlatović, Mario, Barisani-Asenbauer, Talin, Wiedermann, Ursula, Inić-Kanada, Aleksandra, "Supplementary information for the article: Stojanović, M.; Lukić, I.; Marinković, E.; Kovačević, A.; Miljković, R.; Tobias, J.; Schabussova, I.; Zlatović, M.; Barisani-Asenbauer, T.; Wiedermann, U.; Inić-Kanada, A. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. Vaccines 2020, 8 (4), 719. https://doi.org/10.3390/vaccines8040719." in Vaccines, 8, no. 4 (2020):719,
https://hdl.handle.net/21.15107/rcub_intor_643 .

Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia

Stojanović, Marijana; Lukić, Ivana; Marinković, Emilija; Kovačević, Ana; Miljković, Radmila; Tobias, Joshua; Schabussova, Irma; Zlatović, Mario; Barisani-Asenbauer, Talin; Wiedermann, Ursula; Inić-Kanada, Aleksandra

(MDPI, Basel, 2020)

TY  - JOUR
AU  - Stojanović, Marijana
AU  - Lukić, Ivana
AU  - Marinković, Emilija
AU  - Kovačević, Ana
AU  - Miljković, Radmila
AU  - Tobias, Joshua
AU  - Schabussova, Irma
AU  - Zlatović, Mario
AU  - Barisani-Asenbauer, Talin
AU  - Wiedermann, Ursula
AU  - Inić-Kanada, Aleksandra
PY  - 2020
UR  - http://intor.torlakinstitut.com/handle/123456789/552
AB  - Vaccines can have heterologous effects on the immune system, i.e., effects other than triggering an immune response against the disease targeted by the vaccine. We investigated whether monoclonal antibodies (mAbs) specific for tetanus could cross-react with Chlamydia and confer heterologous protection against chlamydial infection. The capability of two tetanus-specific mAbs, namely mAb26 and mAb51, to prevent chlamydial infection has been assessed: (i) in vitro, by performing a neutralization assay using human conjunctival epithelial (HCjE) cells infected with Chlamydia trachomatis serovar B, and (ii) in vivo, by using a guinea pig model of Chlamydia caviae-induced inclusion conjunctivitis. The mAb26 has been superior in comparison with mAb51 in the prevention of chlamydial infection in HCjE cells. The mAb26 has conferred approximate to 40% inhibition of the infection, compared to less than 5% inhibition in the presence of the mAb51. In vivo, mAb26 significantly diminished ocular pathology intensity in guinea pigs infected with C. caviae compared to either the mAb51-treated or sham-treated guinea pigs. Our data provide insights that tetanus immunization generates antibodies which induce heterologous chlamydial immunity and promote protection beyond the intended target pathogen.
PB  - MDPI, Basel
T2  - Vaccines
T1  - Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia
IS  - 4
SP  - 719
VL  - 8
DO  - 10.3390/vaccines8040719
ER  - 
@article{
author = "Stojanović, Marijana and Lukić, Ivana and Marinković, Emilija and Kovačević, Ana and Miljković, Radmila and Tobias, Joshua and Schabussova, Irma and Zlatović, Mario and Barisani-Asenbauer, Talin and Wiedermann, Ursula and Inić-Kanada, Aleksandra",
year = "2020",
abstract = "Vaccines can have heterologous effects on the immune system, i.e., effects other than triggering an immune response against the disease targeted by the vaccine. We investigated whether monoclonal antibodies (mAbs) specific for tetanus could cross-react with Chlamydia and confer heterologous protection against chlamydial infection. The capability of two tetanus-specific mAbs, namely mAb26 and mAb51, to prevent chlamydial infection has been assessed: (i) in vitro, by performing a neutralization assay using human conjunctival epithelial (HCjE) cells infected with Chlamydia trachomatis serovar B, and (ii) in vivo, by using a guinea pig model of Chlamydia caviae-induced inclusion conjunctivitis. The mAb26 has been superior in comparison with mAb51 in the prevention of chlamydial infection in HCjE cells. The mAb26 has conferred approximate to 40% inhibition of the infection, compared to less than 5% inhibition in the presence of the mAb51. In vivo, mAb26 significantly diminished ocular pathology intensity in guinea pigs infected with C. caviae compared to either the mAb51-treated or sham-treated guinea pigs. Our data provide insights that tetanus immunization generates antibodies which induce heterologous chlamydial immunity and promote protection beyond the intended target pathogen.",
publisher = "MDPI, Basel",
journal = "Vaccines",
title = "Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia",
number = "4",
pages = "719",
volume = "8",
doi = "10.3390/vaccines8040719"
}
Stojanović, M., Lukić, I., Marinković, E., Kovačević, A., Miljković, R., Tobias, J., Schabussova, I., Zlatović, M., Barisani-Asenbauer, T., Wiedermann, U.,& Inić-Kanada, A.. (2020). Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. in Vaccines
MDPI, Basel., 8(4), 719.
https://doi.org/10.3390/vaccines8040719
Stojanović M, Lukić I, Marinković E, Kovačević A, Miljković R, Tobias J, Schabussova I, Zlatović M, Barisani-Asenbauer T, Wiedermann U, Inić-Kanada A. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. in Vaccines. 2020;8(4):719.
doi:10.3390/vaccines8040719 .
Stojanović, Marijana, Lukić, Ivana, Marinković, Emilija, Kovačević, Ana, Miljković, Radmila, Tobias, Joshua, Schabussova, Irma, Zlatović, Mario, Barisani-Asenbauer, Talin, Wiedermann, Ursula, Inić-Kanada, Aleksandra, "Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia" in Vaccines, 8, no. 4 (2020):719,
https://doi.org/10.3390/vaccines8040719 . .
2
5
2
4